RG 6016

Drug Profile

RG 6016

Alternative Names: ORY-1001; RG 6016; RO 7051790

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ministry of Economy and Competitiveness; Oryzon
  • Developer Oryzon; Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Small cell lung cancer
  • Preclinical Acute lymphoblastic leukaemia; Solid tumours

Most Recent Events

  • 19 Jul 2017 Roche decides to terminate its licence for RG 6016 due to a portfolio re-prioritisation
  • 25 Jan 2017 Oryzon completes a phase I/II trial in Acute myeloid leukaemia (second-line therapy or greater) in France, Spain and United Kingdom before January 2017
  • 09 Jan 2017 Phase-I clinical trials in Small cell lung cancer (Second-line therapy or greater) in France, Spain, Canada, Denmark (PO) (NCT02913443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top